Resumen
Objetivo: Identificar y evaluar nuevos enfoques de diagnóstico para el Síndrome de Ovario Poliquístico (SOP), centrándose en avances tecnológicos, biomarcadores y criterios diagnósticos recientes que puedan mejorar la precisión y la rapidez en el diagnóstico de esta condición. Métodoa: Esta revisión integrativa se realizó con base en una búsqueda en la base de datos PubMed Central (PMC), utilizando los términos de búsqueda "diagnosable" OR "diagnosis" AND "polycystic ovary syndrome". La búsqueda inicial arrojó 1.241 artículos, de los cuales 63 fueron seleccionados tras aplicar criterios de inclusión y exclusión, resultando en 18 artículos relevantes para un análisis completo. Resultados: Los hallazgos principales destacan avances tecnológicos y biomarcadores prometedores que pueden contribuir a un diagnóstico más preciso del SOP. Las innovaciones discutidas en el estudio sugieren que la combinación de nuevas metodologías podría conducir a una identificación más rápida y eficaz del síndrome, beneficiando el manejo clínico de las pacientes. Consideraciones finales: El estudio subraya la importancia de continuar investigando diagnósticos para el SOP, considerando las limitaciones actuales y la necesidad de más evidencias.
Referencias
AARESTRUP J, et al. Birthweight, childhood body mass index, height and growth, and risk of polycystic ovary syndrome. Obesity Facts, 2021; 14(3): 283-290.
ALADAG H, et al. Galectin-1 an a potential diagostic biomarker in polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences, 2023; 27(6): 2543-2551.
BADEEB A, et al. Dark cortical rim: an MRI feature of polycystic ovarian syndrome. Abdominal Radiology, 2021; 46: 1148-1156.
BOZDAG G, et al. Anti-Müllerian Hormone as a Diagnostic Tool for Polycystic Ovary Syndrome Under Different Diagnostic Criteria Among Unselected Population. Reproductive BioMedicine Online, 2019; 39(3): 522-529.
CRAIG M, et al. Polycystic Ovarian Syndrome in Adolescents: Early Diagnosis and Intervention. Journal of Pediatric Health Care, 2020; 34(2): 166-170.
CUNDUBEY CR. Serum phoenixin-14 Levels of women with polycystic ovary syndrome increase proportionally with BMI. European Review For Medical And Pharmacological Sciences, 2023; 27(8): 3519-3525.
DESWAL R e DANG AS. Dissecting the role of micro-RNAs as a diagnostic marker for polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and sterility, 2020; 113(3): 661-669.
EROGLU S e CAKMAKLIOGULLARI EK. Decreased serum profile of the interleukin-36α in polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology, 2021; 60(6): 1018-1022.
GAO Q, et al. Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure. Frontiers in Endocrinology, 2022; 13: 946504.
HASEGAWA Y, et al. Impact of the difference in diagnostic criteria for adolescent polycystic ovary syndrome excluding polycystic ovarian morphology. Journal of Obstetrics and Gynaecology Research, 2024; 50: 1289–1294.
JARRETT BY, et at. Impact of right–left differences in ovarian morphology on the ultrasound diagnosis of polycystic ovary syndrome. Fertility and Sterility, 2019; 112(5): 939-946.
JIANG Y, et al. Serum asprosin level in diferente subtypes of polycytisc ovary syndrome: a cross-sectional study. Revista da Associação Médica Brasileira, 2021; 67 (4): 590-596.
LIU C, et al. The Associations Between Alanine Aminotransferase and Other Biochemical Parameters in Lean PCOS. Reproductive Sciences, 2023; 30(2): 633-641.
LONE NM, et al. Genotype-independent association between vitamin D deficiency and polycystic ovarian syndrome in Lahore, Pakistan. Scientific Reports, 2020; 10(1): 2290.
LONG J, et al. Screening for a Simple and Effective Indicator of Insulin Resistance in Chinese Reproductive-Aged Women, with the Insulin Clamp Technique as a Reference. Metabolic syndrome and related disorders, 2019; 17(8): 423-429.
MARTIN RF, et al. Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS). Journal of proteome research, 2019; 18(11): 4038-4045.
PAALANNE M, et al. Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm. European Journal of Endocrinology, 2021; 185(2): 279-288.
PARVEEN S, et al. Association of lipid profile and obesity in patients with polycystic ovary syndrome. Endocrine regulations, 2024; 58 (1): 83-90.
REDDY VS, et al. Circulatory Metastin/Kisspeptin-1 (META KISS-1 Study) in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis with Diagnostic Test Accuracy. Reproductive BioMedicine Online, 2019; 39(4): 685-697.
RUDNICKA E, et al. Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. International Journal of Molecular Sciences, 2021; 22(22): 12507.
TEMUR M, et al. Elevated circulating Selenoprotein P levels in patients with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2022; 42(2): 289-293.
WITCHEL SF, et al. Curtailing PCOS. Pediatric research, 2020; 87(2): 353-361.
ZHANG M, et al. The reference value of anti-Müllerian hormone to diagnose polycystic ovary syndrome is inversely associated with BMI: a retrospective study. Reproductive Biology and Endocrinology, 2023; 21(1): 15.
